The 6 key players our Apheresis Equipment report profiles, and other companies free public records show in this market.
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Fresenius Kabi AG |
fresenius-kabi.com (opens in a new tab) | 231 reports |
| 2 | Terumo Corporation | — | 165 reports |
| 3 | B. Braun Melsungen AG | — | 363 reports |
| 4 | Haemonetics Corporation |
haemonetics.com (opens in a new tab) | 33 reports |
| 5 | Asahi Kasei Medical Co., Ltd. |
asahi.com (opens in a new tab) | 33 reports |
| 6 | Terumo BCT, Inc. | — | 33 reports |
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
AstraZeneca |
|
| A2 Biotherapeutics Inc. |
|
| C. R. Bard |
|
Kaneka Corporation |
|
| NxStage (Fresenius) |
|
Johnson & Johnson |
|
| Norfolk Medical Products, Inc. |
|
| Arrowhead Pharmaceuticals |
|
| B. Braun |
|
| ImmunityBio, Inc. |
|
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: FDA 510(k) and PMA databases, 510(k) clearances and PMA approvals since 2015 for devices whose name has this market's words. Retrieved 13 Nov 2026.
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.